{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:52:51Z","timestamp":1777909971548,"version":"3.51.4"},"reference-count":99,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:p>\n                    The quininib series is a novel collection of small-molecule drugs with antiangiogenic, antivascular permeability, anti-inflammatory, and antiproliferative activity. Quininib was initially identified as a drug hit during a random chemical library screen for determinants of developmental ocular angiogenesis in zebrafish. To enhance drug efficacy, novel quininib analogs were designed by applying medicinal chemistry approaches. The resulting quininib drug series has efficacy in\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">ex vivo<\/jats:italic>\n                    models of angiogenesis utilizing human cell lines and tissues.\n                    <jats:italic toggle=\"yes\">In vivo<\/jats:italic>\n                    , quininib drugs reduce pathological angiogenesis and retinal vascular permeability in rodent models. Quininib acts as a cysteinyl leukotriene (CysLT) receptor antagonist, revealing new roles of these G-protein-coupled receptors in developmental angiogenesis of the eye and unexpectedly in uveal melanoma (UM). The quininib series highlighted the potential of CysLT receptors as therapeutic targets for retinal vasculopathies (e.g., neovascular age-related macular degeneration, diabetic retinopathy, and diabetic macular edema) and ocular cancers (e.g., UM).\n                  <\/jats:p>","DOI":"10.1089\/jop.2021.0074","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T16:09:22Z","timestamp":1643386162000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Discovery and Development of the Quininib Series of Ocular Drugs"],"prefix":"10.1177","volume":"38","author":[{"given":"Niamh","family":"Mahon","sequence":"first","affiliation":[{"name":"UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland."},{"name":"UCD Conway Institute, University College Dublin, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayleigh","family":"Slater","sequence":"additional","affiliation":[{"name":"UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland."},{"name":"UCD Conway Institute, University College Dublin, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"O'Brien","sequence":"additional","affiliation":[{"name":"UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland."},{"name":"UCD Conway Institute, University College Dublin, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Alvarez","sequence":"additional","affiliation":[{"name":"UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland."},{"name":"UCD Conway Institute, University College Dublin, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Reynolds","sequence":"additional","affiliation":[{"name":"UCD Conway Institute, University College Dublin, Dublin, Ireland."},{"name":"UCD School of Veterinary Medicine, Veterinary Sciences Center, University College Dublin, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breand\u00e1n","family":"Kennedy","sequence":"additional","affiliation":[{"name":"UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland."},{"name":"UCD Conway Institute, University College Dublin, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-007-9065-1"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.11.001"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.4.547"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094809"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30393-5"},{"key":"e_1_3_4_7_2","unstructured":"National Institute for Care Excellence (UK). Age-related Macular Degeneration: Diagnosis and Mangement. London: NICE (UK);. 2018."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30488-5"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.10.001"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(01)00012-X"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1387\/ijdb.041895ms"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.066"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-20050701-14"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197670"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2016.1154174"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.064"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.05.017"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.86"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4627"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2091"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-213X-7-114"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007867"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381320-6.00007-2"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00042-9"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000068685.72914.7E"},{"key":"e_1_3_4_33_2","first-page":"299","article-title":"Phenotypic vs","volume":"93","author":"Swinney D.C.","year":"2013","unstructured":"Swinney D.C. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin. Pharmacol. Ther., 93:299\u2013301, 2013.","journal-title":"target-based drug discovery for first-in-class medicines. Clin. Pharmacol. Ther."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3480"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.2002.0711"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(96)00423-1"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470559277.ch110252"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-017-0212-4"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.10.016"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mod.2009.01.002"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.05.024"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.710665"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm7015478"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00099a011"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000312669"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(82)90060-0"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2010.03630.x"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.747766"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12613748"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep34523"},{"key":"e_1_3_4_51_2","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith L.E.","year":"1994","unstructured":"Smith L.E., , Wesolowski E., , McLellan A., et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35:101\u2013111, 1994.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.04.004"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1997.00170.x"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7909"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2009.09.010"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-009-9222-5"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(03)00467-8"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1021\/nn500136z"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0158-0"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.275"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1159\/000495113"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000584"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3549"},{"key":"e_1_3_4_64_2","first-page":"2900","article-title":"Microvessel count predicts survival in uveal melanoma","volume":"56","author":"Foss A.J.","year":"1996","unstructured":"Foss A.J., , Alexander R.A., , Jefferies L.W., et al. Microvessel count predicts survival in uveal melanoma. Cancer Res. 56:2900\u20132903, 1996.","journal-title":"Cancer Res"},{"key":"e_1_3_4_65_2","first-page":"2471","article-title":"Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma","volume":"40","author":"Makitie T.","year":"1999","unstructured":"Makitie T., , Summanen P., , Tarkkanen A., , and Kivela T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest. Ophthalmol. Vis. Sci. 40:2471\u20132480, 1999.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060834"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052669"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1159\/000329591"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4755"},{"key":"e_1_3_4_70_2","first-page":"2454","article-title":"Bevacizumab and intraocular tumors: an intriguing paradox","volume":"18","author":"el Filali M.","year":"2012","unstructured":"el Filali M., , Ly L.V., , Luyten G.P., et al. Bevacizumab and intraocular tumors: an intriguing paradox. Mol. Vis. 18:2454, 2012.","journal-title":"Mol. Vis"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.08.040"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-018-9751-z"},{"key":"e_1_3_4_73_2","first-page":"A68","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge","volume":"19","author":"Tomczak K.","year":"2015","unstructured":"Tomczak K., , Czerwi\u0144ska P., , and Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. 19:A68\u2013A77, 2015.","journal-title":"Contemp. Oncol"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102950"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15699"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506454200"},{"key":"e_1_3_4_77_2","first-page":"1152","article-title":"Oral montelukast is associated with decreased odds of diabetic retinopathy","volume":"62","author":"Pham B.","year":"2021","unstructured":"Pham B., , Matsumiya W., , Akhavanrezayat A., et al. Oral montelukast is associated with decreased odds of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 62:1152, 2021.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_78_2","first-page":"275","article-title":"Association of oral montelukast with reduced odds of developing neovascular age-related macular degeneration","volume":"62","author":"Karaca I.","year":"2021","unstructured":"Karaca I., , Matsumiya W., , Akhavanrezayat A., et al. Association of oral montelukast with reduced odds of developing neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci., 62:275, 2021.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-195792"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.19"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89482-z"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00508"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1481"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.05.035"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.11.007"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1636031"},{"key":"e_1_3_4_87_2","article-title":"Sustained suppression of VEGF for treatment of retinal\/choroidal vascular diseases","author":"Campochiaro P.A.","year":"2020","unstructured":"Campochiaro P.A., , and Akhlaq A. Sustained suppression of VEGF for treatment of retinal\/choroidal vascular diseases. Prog. Retin. Eye Res. 100921, 2020.","journal-title":"Prog. Retin. Eye Res"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.4110"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.08.022"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.039"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20170130-02"},{"key":"e_1_3_4_96_2","unstructured":"Genentech 2021. FDA Approves Genentech's Susvimo a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD). Available at https:\/\/www.gene.com\/media\/press-releases\/14935\/2021-10-22\/fda-approves-genentechs-susvimo-a-first-?s=03 Accessed November3 2021."},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.024"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.04.020"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1159\/000381865"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04478"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2021.0074","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0074","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:44Z","timestamp":1777646684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2021.0074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"alternative-id":["10.1089\/jop.2021.0074"],"URL":"https:\/\/doi.org\/10.1089\/jop.2021.0074","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}